A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

NCT02080078 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped REB decision

Conditions

Non-small Cell Lung Cancer
Advanced Solid Malignancies

Interventions

DRUG: Theophylline
DRUG: Erlotinib

Sponsor

AHS Cancer Control Alberta

Collaborators

[object Object]